期刊文献+

β-榄香烯联合三苯氧胺抑制乳腺癌MCF-7细胞生长的实验研究 被引量:4

Experimental study on β-elemene combined with tamoxifen inhibiting the apoptosis of breast cancer cell strain MCF-7
暂未订购
导出
摘要 目的:研究β-榄香烯联合三苯氧胺对乳腺癌MCF-7细胞生长有无协同抑制作用,并探讨其可能的机制。方法:采用MTT法检测β-榄香烯联合三苯氧胺对MCF-7细胞的增殖抑制作用,流式细胞仪测定细胞周期和凋亡率,免疫组化SP法检测bcl-2、pS2表达变化。结果:不同剂量的β-榄香烯联合治疗剂量的三苯氧胺,吸光度均值较单用三苯氧胺明显下降,相应的细胞抑制作用明显上升;流式细胞仪检测G/G期细胞比例增加,用药后凋亡率升高,bcl-2、pS2在联合用药后表达明显下调。结论:β-榄香烯使三苯氧胺对乳腺癌MCF-7细胞的抑制作用显著增强,提示榄香烯与三苯氧胺具有协同增效作用,其作用机制与影响细胞周期进程,协同促进凋亡,下调bcl-2、pS2表达有关。 Objective: To investigate whether MCF -7 cell strain of breast cancer can be restrained by [3 - elemene in coordination with tamoxifen(TAM) , and its possible mechanism. Methods: MTr method was used to test the inhibitory effect of β - elemence combined with TAM on MCF - 7 cell strain, FCM mensurate cell cycle and the percentage of apoptosis, SP method to test bcl - 2, pS2 expression change. Results. Different dosage of β - elemene and curative dose of tamoxifen reduced absorptions significantly compared with the group of tamoxifen alone, meanwhile the inhibitory rates increased significantly. The increaseing of G0/G1 phase cell proportion tested by FCM, the percentage of apoptosis elevated after treated by the medicine, bcl- 2, pS2 express obviously declined. Conclusion: β -elemene enhances the inhibitory effect of tamoxifen on MCF -7 cell strain of breast cancer significantly ,which in- dicates the inhibition of TAM on breast cancer cell strain can be synergized by β - elemene, the mechanism concern with influence cell cycle, promotes apoptosis, and downregnlates bcl -2, pS2 expression.
出处 《现代肿瘤医学》 CAS 2008年第4期510-514,共5页 Journal of Modern Oncology
基金 陕西省自然科学基金资助项目[20021210-G3(05)]
关键词 Β-榄香烯 三苯氧胺 MCF-7 协同抑制作用 β - elemene tamoxifen MCF - 7 synergize
  • 相关文献

参考文献10

二级参考文献14

  • 1Tanner M, Gancberg D, Di L A, et al. Chromogenic in situ hybridization: a practical alternative for flouresence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer sample[J]. Am J Pathol, 2000, 157(5): 1467-1472.
  • 2Meijers H H, Brekelmans C T, Menke P M, et al. Use of genetic test and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation[J]. J Clin Oncol, 2003, 21: 1675-1681.
  • 3Birner P, Oberhuber G, Stani J, et al. Evaluation of the united states food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer[J]. Clin Cancer Res, 2001, 7(6): 1669-1675.
  • 4Apantaku L M. Breast cancer diagnosis and screening[J]. Am Fam Physician, 2000, 62: 596-602.
  • 5Lipton A, Ali S M, Leitzed K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer[J]. J Clin Oncol, 2002, 20(6): 1467-1472.
  • 6Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J ]. N Engl J Med, 2001, 344(11): 783-7921.
  • 7Miles D W. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting[J]. Breast Cancer Res, 2001, 3(6): 380-3841.
  • 8King M C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention Trial[J]. JAMA, 2001, 286(18): 2551-2556.
  • 9Narod S A, Brunet J S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case?control study[J]. Lancet, 2000,356:1876-1881.
  • 10Meijers-Heijboer H, Van-Geel B, Van-Putten W L, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation[J]. N Engl J Med, 2001, 345:159-164.

共引文献200

同被引文献69

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部